Should my children get tested for APOE4? What the guidelines actually say

Short answer: No — and for children that isn't a judgement call we're making, it's settled professional guidance. The joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors are clear that predictive testing for Alzheimer's should not be offered to children: it's for adults who can decide for themselves. For adult children the position is softer but still points the same way — the ACMG has named APOE testing as something clinicians shouldn't order as a predictive test, because an ε4 result is neither necessary nor sufficient to cause Alzheimer's and wouldn't change a healthy person's medical care. There's also a practical cost most articles skip: a result creates a disclosable record that US genetic-privacy law does not protect from life, long-term-care or disability insurers. What you can usefully pass on is the part that works whether or not anyone tests.

This is educational, not medical advice. If you're weighing genetic testing for yourself or anyone in your family, a genetic counsellor is the right person to talk to — that conversation is itself part of what the guidelines recommend.

What you actually passed on

Everyone has two copies of the APOE gene, one from each parent, and each copy comes in one of three common versions: ε2, ε3 or ε4. If you carry one ε4, each of your children had a 50% chance of inheriting that particular copy — the same coin-flip as any other gene. If you carry two, they each inherited one for certain.

That sounds alarming until you put it next to how common ε4 is. Roughly a quarter of people carry at least one copy, and only about a third of those carriers ever develop Alzheimer's. Most ε4 carriers do not get the disease. Many people who do get it carry no ε4 at all.

This is the difference between a risk factor and a cause, and it's the whole reason the guidance says what it says.

What the professional guidance says, in its own words

Most articles on this question give you a balanced-sounding "it's a personal decision." The professional bodies were more direct than that.

The reference document is the joint practice guideline issued by the American College of Medical Genetics and the National Society of Genetic Counselors, published in Genetics in Medicine in 2011 and updated by a 2019 addendum. It exists precisely because, as its own authors put it, "few clinicians are prepared to address the genetic risks of Alzheimer disease with their patients."

On children it is not ambiguous. Predictive testing for Alzheimer's should not be offered to children — it is for adults who can decide for themselves whether they want the information. US insurance medical policies follow the same line, classing predictive Alzheimer's genetic testing under 18 as not medically necessary.

The principle behind that isn't specific to Alzheimer's. It's a long-standing one in clinical genetics: when a test predicts an adult-onset condition and there is nothing to do about it in childhood, the child's own future right to decide — including the right not to know — outweighs a parent's wish to find out.

On APOE testing generally, the ACMG has separately named it as a test clinicians should not order to predict Alzheimer's. The reasoning it gives is that APOE is a susceptibility gene, that an ε4 allele is neither necessary nor sufficient to cause the disease, and that the risk it confers is tangled up with other genes, sex, environment and possibly ancestry — leaving the test with limited clinical utility and poor predictive value. "Limited clinical utility" is the operative phrase. It means knowing the answer would not change what a doctor does.

And for adult children? Here it is genuinely softer than a flat prohibition, and we'd rather say so. The guideline itself notes that APOE testing "can be valuable and safe in certain contexts" — with counselling, for someone who has thought about what they would do with the answer. Predictive testing in people without symptoms is still generally treated as investigational by US payers, and direct-to-consumer APOE testing is specifically not advised. So: your adult children can choose to test, and it's their decision rather than yours or ours. What the guidance doesn't support is anyone recommending it to them.

The one situation where APOE genotyping is standard — and why it doesn't apply here

There's a real exception, and it's worth knowing precisely because it gets misread as a general endorsement of testing.

If someone has already been diagnosed with mild cognitive impairment or early Alzheimer's and is being considered for an anti-amyloid drug such as lecanemab, APOE genotyping is now recommended before treatment. The reason is safety: the risk of ARIA — amyloid-related imaging abnormalities, a known side effect involving brain swelling or small bleeds — rises with the number of ε4 copies, so the result changes how the drug is used and monitored.

Notice what that is and isn't. It is a treatment-safety test in someone who already has a diagnosis. It is not a prediction test in a healthy 34-year-old. The same genotype serves a purpose in one setting and none in the other.

We go through the full testing decision for yourself — including the two-copy case — in should I get the Alzheimer's gene test?

The consequence most articles leave out — and it lands harder on your kids

If your children test, the result becomes part of their record decades before it could plausibly matter. And US genetic-privacy law is narrower than most people assume.

GINA — the Genetic Information Nondiscrimination Act — covers health insurance and employment. It does not cover life insurance, long-term-care insurance or disability insurance. In most states, those insurers can ask about genetic test results and use them in underwriting.

For a 62-year-old who already holds their policies, that's a manageable consideration. For a 30-year-old who has not yet bought life insurance, taken out a mortgage that requires it, or thought about long-term-care cover, it is a materially bigger one. The younger the person, the more the disclosure costs and the less the information is worth — which is close to the exact opposite of how people intuitively weigh it.

Direct-to-consumer kits add a second layer. The genetic-privacy questions raised by 23andMe's 2025 bankruptcy — what happens to a database of people's genomes when the company holding it is sold — apply to anyone who tests that way, at any age.

So what do you tell them?

Here is the part worth passing on, and it's better news than the test would have been.

Researchers pooled three multidomain lifestyle trials — FINGER, J-MINT and MAPT — and reported in December 2025 that APOE4 carriers appeared to benefit more from structured lifestyle change than non-carriers (interaction p = 0.035). The authors call the finding preliminary, and it should be read that way. But its direction matters enormously for this conversation: higher genetic risk did not mean less to gain.

Which means the useful answer to "what does this mean for me?" doesn't depend on anyone's genotype at all. The things worth doing are the same either way — and the earlier they start, the more room they have to work, since several of the strongest risk factors are midlife ones.

A concrete version, for an adult child in their thirties or forties:

• Know your blood pressure. It's the single best-evidenced midlife lever there is. → blood pressure and dementia
• Protect your hearing — including at gigs, on building sites and in headphones. Hearing loss is one of the largest modifiable factors and it accumulates quietly. → hearing loss and dementia
• Keep an eye on blood sugar and cholesterol at routine check-ups. → blood sugar · cholesterol
• Move, sleep and stay connected — the unglamorous three. → exercise · sleep · loneliness
• Don't smoke, and treat depression as the health issue it is. → smoking and dementia risk · is it anxiety or dementia?

None of that requires a test result. All of it is on the 2024 Lancet Commission's list of 14 modifiable factors, which together account for around 45% of dementia cases worldwide.

One more thing about the conversation itself

If you've had a result and you're deciding whether to tell your children at all, that's a family question rather than a medical one, and there isn't a right answer we can hand you.

What genetic counsellors generally point out is that your result carries information about them whether they asked for it or not — so the choice is less "should they know" than "should they be told, and how." People react very differently: some find it motivating, some find it frightening, and some would genuinely rather not have been told. Those are all legitimate.

If it would help to have that conversation with someone trained for it, a genetic counsellor can see the whole family, not just the person who tested. That's what they're for, and it's what the guidelines recommend regardless of which way the decision goes.

More on this: is dementia hereditary? · does Alzheimer's skip a generation? · is dementia inherited from your mother or father? · should I get the Alzheimer's gene test? · can you reduce your dementia risk? · check your dementia risk

How we research and review our content →

This article is educational and is not medical advice, diagnosis, or treatment. The studies cited describe findings in general populations, not any individual. Solenna is not a medical device and does not diagnose, prevent, treat, or cure Alzheimer's disease or any other condition. Risk reduction means lowering probability, not eliminating it; individual results vary and no outcome is guaranteed. Decisions about genetic testing, disclosure within a family, medication or treatment should be made with a qualified clinician or certified genetic counsellor.